Defining the role of BARD1 in nucleosomal ubiquitylation

定义 BARD1 在核小体泛素化中的作用

基本信息

  • 批准号:
    10610818
  • 负责人:
  • 金额:
    $ 52.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY BARD1 (BRCA1-Associated RING Domain protein-1) is an essential partner of the breast and ovarian cancer tumor-suppressor protein, BRCA1, and is included in a panel of genes used to evaluate patients with suspected hereditary cancer predisposition, especially breast and ovarian cancers. Despite this, little is known about the cellular role of BARD1. This project aims to address this serious gap in knowledge by defining at a molecular level how BARD1 contributes to DNA damage repair and to transcriptional repression. An ultimate goal is to enable predictions regarding potential loss-of-function phenotypes for mutations identified in patients. BRCA1 and its obligate partner BARD1 form a heterodimeric complex that is implicated in numerous cellular processes, most notably, transcriptional regulation and DNA repair via homologous recombination. The sole enzymatic activity directly associated with the BRCA1/BARD1 complex is as an E3 Ubiquitin ligase. The RING domains of BRCA1 and BARD1 specifically and uniquely target positions on the tail of nucleosomal histone H2A. The ability of BRCA1/BARD1 to place these Ub marks is essential to both its transcriptional repression of certain genes and its function in DNA damage repair by homologous recombination. While the RING of BRCA1 is required for all ligase activity, breast cancer patient mutations in the RING of BARD1 display loss-of-function specifically for ubiquitylation of H2A. A newly determined cryo-EM structure of the BRCA1/BARD1 RING domains sitting atop a nucleosome reveals that BARD1 dictates the orientation of the E3 ligase and, therefore, determines the site(s) of modification on H2A. In this project, we will build on this exciting new structural insight to address how regions outside BARD1’s RING contribute to its function as an essential partner of BRCA1.
项目摘要 BARD 1(BRCA 1相关环结构域蛋白-1)是乳腺的重要伴侣, 卵巢癌肿瘤抑制蛋白BRCA 1,包括在一组基因中, 评估疑似遗传性癌症易感性的患者,尤其是乳腺癌和卵巢癌 癌的尽管如此,人们对BARD 1的细胞作用知之甚少。该项目旨在 通过在分子水平上定义BARD 1如何发挥作用, DNA损伤修复和转录抑制。最终目标是使 预测患者中鉴定的突变的潜在功能丧失表型。 BRCA 1和其专性伴侣BARD 1形成异二聚体复合物,其涉及 许多细胞过程,最值得注意的是,转录调节和DNA修复, 同源重组唯一的酶活性直接与 BRCA 1/BARD 1复合物是E3泛素连接酶。BRCA 1和BRCA 2的RING结构域 BARD 1特异性和独特地靶向核小体组蛋白H2 A尾部的位置。的 BRCA 1/BARD 1放置这些Ub标记的能力对于其转录和表达都是至关重要的。 抑制某些基因及其在DNA损伤修复中的功能 重组虽然BRCA 1的RING是所有连接酶活性所必需的,但乳腺癌患者 BARD 1的RING中的突变显示出H2 A的泛素化特异性功能丧失。一 新确定的BRCA 1/BARD 1 RING结构域的冷冻电镜结构位于一个 核小体揭示BARD 1决定E3连接酶的方向,因此, 确定H2 A上的修饰位点。在这个项目中,我们将建立在这个令人兴奋的新的 结构洞察力,以解决BARD 1的RING以外的区域如何有助于其作为一个 BRCA 1的重要伙伴。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER S BRZOVIC其他文献

PETER S BRZOVIC的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER S BRZOVIC', 18)}}的其他基金

Defining the role of BARD1 in nucleosomal ubiquitylation
定义 BARD1 在核小体泛素化中的作用
  • 批准号:
    10368107
  • 财政年份:
    2021
  • 资助金额:
    $ 52.72万
  • 项目类别:
Defining the role of BARD1 in nucleosomal ubiquitylation
定义 BARD1 在核小体泛素化中的作用
  • 批准号:
    10231875
  • 财政年份:
    2021
  • 资助金额:
    $ 52.72万
  • 项目类别:
Unconventional Interactions of Human Ubiquitin Conjugating Enzymes
人类泛素结合酶的非常规相互作用
  • 批准号:
    8528627
  • 财政年份:
    2012
  • 资助金额:
    $ 52.72万
  • 项目类别:
Unconventional Interactions of Human Ubiquitin Conjugating Enzymes
人类泛素结合酶的非常规相互作用
  • 批准号:
    8716782
  • 财政年份:
    2012
  • 资助金额:
    $ 52.72万
  • 项目类别:
Unconventional Interactions of Human Ubiquitin Conjugating Enzymes
人类泛素结合酶的非常规相互作用
  • 批准号:
    8293759
  • 财政年份:
    2012
  • 资助金额:
    $ 52.72万
  • 项目类别:
Unconventional Interactions of Human Ubiquitin Conjugating Enzymes
人类泛素结合酶的非常规相互作用
  • 批准号:
    9276349
  • 财政年份:
    2012
  • 资助金额:
    $ 52.72万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.72万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了